PURPOSE:To assess the efficacy of topical cyclosporine 0.05%(Restasis)in patients with herpes simplex virus nonnecrotizing stromal keratitis unresponsive to topical prednisolone.DESIGN:Prospective case series.METHODS:...PURPOSE:To assess the efficacy of topical cyclosporine 0.05%(Restasis)in patients with herpes simplex virus nonnecrotizing stromal keratitis unresponsive to topical prednisolone.DESIGN:Prospective case series.METHODS:Patients with herpes simplex virus stromal keratitis(n=12)that was unresponsive to topical prednisolone acetate 1% for at least four weeks were evaluated at a single site.Eyes were treated with topical cyclosporine twice a day and begun on a rapid prednisolone taper.Visual acuity,slit-lamp appearance,intraocular pressure,and corneal sensitivity were evaluated every two weeks for at least three months.RESULTS:Stromal keratitis resolved with cyclosporine in 10 of 12 patients after one month.Themean lesion area decreased more with cyclosporine than with prednisolone(2.0 mm with cyclosporine compared with 0.25 mm with prednisolone).After stopping cyclosporine therapy,four patients had recurrence of stromal keratitis.CONCLUSION:This series suggests that herpes simplex virus stromal keratitis can be treated effectively with topical cyclosporine,particularly in cases that are not responsive to topical prednisolone.展开更多
Background: A new long-acting (LA) formulation of carteolol 2%instilled once daily has been shown to provide a therapeutic effect similar to that of the regular formulation of carteolol 2%instilled twice daily. This s...Background: A new long-acting (LA) formulation of carteolol 2%instilled once daily has been shown to provide a therapeutic effect similar to that of the regular formulation of carteolol 2%instilled twice daily. This study was designed to test whether the new formulation reduces the systemic delivery of carteolol. Methods: In this double-masked, randomised, intrasubject comparative study, 23 patients with bilateral primary open-angle glaucoma or bilateral ocular hypertension received sequentially, according to the randomised order of administration, each of the 2 following treatments: carteolol 2%LA once daily for 2 months and carteolol 2%regular twice daily for 2 months. Treatments were instilled in both eyes throughout the study period. At the end of each period of treatment, blood samples were taken immediately before the last morning instillation (residual time), then 30 min, 1 h, 2 h and 4 h after this instillation in order to measure the carteolol plasma concentrations. Results: The mean values of maximal plasma concentration (Cmax), residual level and area under the curve obtained following carteolol 2%LA treatment were significantly lower than the values obtained after carteolol 2%regular treatment (mean±SD): Cmax (ng/ml): 1.72±0.85 versus 3.64±3.65; residual level (ng/ml): 0.70±0.58 versus 1.80±0.84; area under the curve (ng/ml×h): 5.50±2.66 versus 10.27±5.46. Regarding safety, two drug-related, non-serious adverse events were reported in the LA group: one case of moderate, superficial, punctate keratitis and one case of "bitter taste in the throat". Both treatments appeared to be well tolerated. Conclusions: The data from this study showed that the systemic delivery of carteolol is lower for the once-daily LA formulation than for the regular twice-daily formulation. Consequently, longacting carteolol eye-drops should reduce the risk of β-blocking systemic side effects.展开更多
Purpose:Topical steroid use is usually avoided in cases of corneal epithelial defect.We evaluated the effect of topical steroid treatment on corneal epithelial healing after epithelial debridement in vitreoretinal sur...Purpose:Topical steroid use is usually avoided in cases of corneal epithelial defect.We evaluated the effect of topical steroid treatment on corneal epithelial healing after epithelial debridement in vitreoretinal surgery.Methods:Our study population included 85 eyes undergoing vitreoretinal surgeries in our clinic.We prospectively compared the duration of corneal epithelial wound healing in 43 eyes in which topical dexamethasone was used with that in 42 eyes in which topical dexamethasone was not used in the early postoperative period after epithelial debridement.Factors that may retard corneal epithelial healing,including pre-and intraoperative topical solutions,median operative time,the presence of diabetes mellitus,prior ocular surgeries,pseudophakia,aphakia and the presence of intraocular gas or silicone oil in aphakic patients,were not significantly different between the two groups.Results:The mean corneal epithelial defect closure time was 59.7± 2.6 hours(mean± SEM)in the group receiving topical steroid treatment,and 61.9± 2.6 hours in the group that did not receive steroids.Conclusion:Topical dexamethasone administered five times/day did not significantly retard corneal epithelial healing in subjects undergoing vitreoretinal surgery with postoperative topical steroid treatment,compared with subjects who did not receive steroid treatment.展开更多
PURPOSE: To study whether topical ibopamine effectively increases the intraocular pressure in patients with ocular hypotony after vitreoretinal surgery,uveitis,or penetrating trauma. DESIGN: A prospective randomized,d...PURPOSE: To study whether topical ibopamine effectively increases the intraocular pressure in patients with ocular hypotony after vitreoretinal surgery,uveitis,or penetrating trauma. DESIGN: A prospective randomized,double-blind,placebo controlled,crossover study. METHODS: In ten patients with ocular hypotony,an ibopamine 2% solution or placebo eyedrop was administered at 8 am and frequent applanation tonometry was performed during 10 hours on 2 days,2 weeks apart. RESULTS: The mean IOP integral after administration of ibopamine was 2.4 mm Hg higher (95% CI for median difference in AUC over 480 minutes .010) compared with placebo. CONCLUSIONS: The results of the study show that an ibopamine 2% eyedrop twice a day may increase the IOP for a period of over 8 hours in patients with hypotony.展开更多
文摘PURPOSE:To assess the efficacy of topical cyclosporine 0.05%(Restasis)in patients with herpes simplex virus nonnecrotizing stromal keratitis unresponsive to topical prednisolone.DESIGN:Prospective case series.METHODS:Patients with herpes simplex virus stromal keratitis(n=12)that was unresponsive to topical prednisolone acetate 1% for at least four weeks were evaluated at a single site.Eyes were treated with topical cyclosporine twice a day and begun on a rapid prednisolone taper.Visual acuity,slit-lamp appearance,intraocular pressure,and corneal sensitivity were evaluated every two weeks for at least three months.RESULTS:Stromal keratitis resolved with cyclosporine in 10 of 12 patients after one month.Themean lesion area decreased more with cyclosporine than with prednisolone(2.0 mm with cyclosporine compared with 0.25 mm with prednisolone).After stopping cyclosporine therapy,four patients had recurrence of stromal keratitis.CONCLUSION:This series suggests that herpes simplex virus stromal keratitis can be treated effectively with topical cyclosporine,particularly in cases that are not responsive to topical prednisolone.
文摘Background: A new long-acting (LA) formulation of carteolol 2%instilled once daily has been shown to provide a therapeutic effect similar to that of the regular formulation of carteolol 2%instilled twice daily. This study was designed to test whether the new formulation reduces the systemic delivery of carteolol. Methods: In this double-masked, randomised, intrasubject comparative study, 23 patients with bilateral primary open-angle glaucoma or bilateral ocular hypertension received sequentially, according to the randomised order of administration, each of the 2 following treatments: carteolol 2%LA once daily for 2 months and carteolol 2%regular twice daily for 2 months. Treatments were instilled in both eyes throughout the study period. At the end of each period of treatment, blood samples were taken immediately before the last morning instillation (residual time), then 30 min, 1 h, 2 h and 4 h after this instillation in order to measure the carteolol plasma concentrations. Results: The mean values of maximal plasma concentration (Cmax), residual level and area under the curve obtained following carteolol 2%LA treatment were significantly lower than the values obtained after carteolol 2%regular treatment (mean±SD): Cmax (ng/ml): 1.72±0.85 versus 3.64±3.65; residual level (ng/ml): 0.70±0.58 versus 1.80±0.84; area under the curve (ng/ml×h): 5.50±2.66 versus 10.27±5.46. Regarding safety, two drug-related, non-serious adverse events were reported in the LA group: one case of moderate, superficial, punctate keratitis and one case of "bitter taste in the throat". Both treatments appeared to be well tolerated. Conclusions: The data from this study showed that the systemic delivery of carteolol is lower for the once-daily LA formulation than for the regular twice-daily formulation. Consequently, longacting carteolol eye-drops should reduce the risk of β-blocking systemic side effects.
文摘Purpose:Topical steroid use is usually avoided in cases of corneal epithelial defect.We evaluated the effect of topical steroid treatment on corneal epithelial healing after epithelial debridement in vitreoretinal surgery.Methods:Our study population included 85 eyes undergoing vitreoretinal surgeries in our clinic.We prospectively compared the duration of corneal epithelial wound healing in 43 eyes in which topical dexamethasone was used with that in 42 eyes in which topical dexamethasone was not used in the early postoperative period after epithelial debridement.Factors that may retard corneal epithelial healing,including pre-and intraoperative topical solutions,median operative time,the presence of diabetes mellitus,prior ocular surgeries,pseudophakia,aphakia and the presence of intraocular gas or silicone oil in aphakic patients,were not significantly different between the two groups.Results:The mean corneal epithelial defect closure time was 59.7± 2.6 hours(mean± SEM)in the group receiving topical steroid treatment,and 61.9± 2.6 hours in the group that did not receive steroids.Conclusion:Topical dexamethasone administered five times/day did not significantly retard corneal epithelial healing in subjects undergoing vitreoretinal surgery with postoperative topical steroid treatment,compared with subjects who did not receive steroid treatment.
文摘PURPOSE: To study whether topical ibopamine effectively increases the intraocular pressure in patients with ocular hypotony after vitreoretinal surgery,uveitis,or penetrating trauma. DESIGN: A prospective randomized,double-blind,placebo controlled,crossover study. METHODS: In ten patients with ocular hypotony,an ibopamine 2% solution or placebo eyedrop was administered at 8 am and frequent applanation tonometry was performed during 10 hours on 2 days,2 weeks apart. RESULTS: The mean IOP integral after administration of ibopamine was 2.4 mm Hg higher (95% CI for median difference in AUC over 480 minutes .010) compared with placebo. CONCLUSIONS: The results of the study show that an ibopamine 2% eyedrop twice a day may increase the IOP for a period of over 8 hours in patients with hypotony.
